Appln. No. 10/807,620 Amendment dated February 18, 2010 Reply to Office Action of October 26, 2009

The listing of claims will replace all prior versions and listing of claims in the application:

## Listing of Claims:

Claims 1-21. (cancelled).

Claim 22. (Cancel)

Claims 23, 24 and 25. (cancelled)

Claim 26. (cancel)

Claim 27. (currently amended)

The kit of claim 35 22, wherein the resulting said low circulating plasma concentration of suramin in said patient is between about 10 and 200 µM.

Claim 28. (currently amended) The kit of claim 27, the resulting said-low circulating plasma concentration of suramin in said patient is between about 10 and 50 µM.

Cancel Claims 29, 30, and 31.

Claim 32. (currently amended)

The kit of claim 27 22, wherein said nomogram results in a patient circulating concentration of suramin a suramin dose is administered such that a eencentration of between about 10 to about 50 µM over 48 hours is achieved in a patient.

Claim 33. (currently amended)

The kit of claim <u>35</u> 22, wherein two-thirds of the <u>calculated</u> individual dose therapeutically effective-amount of suramin <u>for each treatment</u> is given on the first day and the remaining one-third of the <u>calculated individual dose</u> therapeutically effective amount is given about 24 hours later.

Claim 34. (cancel)

Claim 35. (new) A kit for providing individual treatment of suramin to a patient, comprising:

 (a) not substantially in excess of about 800 mg of suramin formulated in a pharmaceutical carrier; and

- (b) a dosing nomogram to calculate the dose of suramin for a patient based on the body surface area and the timing of the treatment for said patient, whereby the dose is calculated as the multiplication product of (squared value of said patient's body surface area or BSA) and (numerical value of a factor or FACTOR), in accordance to the following table: said calculation comprising:
  - (b1) calculating the first treatment dose as the multiplication product of (squared value of said patient's BSA) and (125); and
  - (b2) calculating the second and subsequent doses as the multiplication product of (squared value of said patient's BSA) and (numerical value of FACTOR), wherein FACTOR is determined by the elapsed days since last suramin treatment

said nomogram table comprising:

Nomogram For Calculating Suramin Dose

Cycle 1*	FACTOR = 125
Second and subsequent treatments use different values of FACTOR in accordance with patient's time of treatment, expressed as elapsed time (in days) since the start of the previous treatment	FACTOR
7	39
8	43
9	47
10	51
11	55
12	58
13	61
14	64
15	67
16	69

17	72
18	74
19	76
20	78
21	80
22	82
23	84
24	86
25	87
26	88
27	90
28	91
29	92
30	93
31	94
32	95
33	96
34	97
35	98
36	98
37	99
38	100
39	100
41	102
42	102

Appln. No. 10/807,620 Amendment dated February 18, 2010 Reply to Office Action of October 26, 2009

44	103
47	104
49	105
52	106
55	106

and whereby the dose for elapsed times not included in the above nomogram table, being less than 7 days or more than 55 days, is calculated in accordance to the following equation:

Subsequent cycle dose (mg) = First dose \*  $(1-e^{-k \cdot t}) = 125*BSA^{2*}(1-e^{-k \cdot t})$  Eq. 16 wherein

- "BSA" is body surface area in units of m2,
- "BSA" is the squared value of BSA and is entered as a unitless value,
- "k" is the rate constant of decline of suramin concentrations in plasma in units of 1/hour, and is 0.0026 1/hour,
- "t" is time after suramin administration in units of hours.